Friday, July 09, 2010

The University of North Carolina at Charlotte

Details

Project TitleT-lymphocyte Immunosuppression Compositions
Track Code2004-061
Websitehttps://research.uncc.edu/technology-transfer
Short Description

Purified Salp15 and fragments of Salp15 that are capable of modulating activation of CD4+ T Cells for use in immunoinflammatory disorders.

Abstract

Novel compositions of purified Salp15 and fragments of Salp15 that are capable of binding to T-lymphocytes and modulating Class II MHC-mediated T-lymphocyte activation via the T cell receptor activation of CD4+ T cells and consequently capable of acting as immunomodulators and anti-inflammatory agents.  These compositions may be useful for immunoinflammatory disorders such as asthma, allergic intraocular inflammatory diseases, rheumatoid arthritis, atopic dermatitis, atopic eczema, type I diabetes, hemolytic anemia, inflammatory dermatoses, inflammatory bowel or gastrointestinal disorders (e.g., Crohn’s disease and ulcerative colitis), multiple sclerosis, myasthenia gravis, pruritus/ inflammation, psoriasis, cirrhosis, and systemic lupus erythematosus.

U. S. Patents: 8,461,103; 8,119,589 

Patent Pending: PCT/US2005/032843

 
Tagspurified, Salp15, fragment, binding, lymphocytes, modulating, Class II MHC, t-lymphocyte, activation, receptor, CD4+ immunomodulators, anti-inflammatory, compositions, immunoinflammatory, disorders, asthma, allergic intraocular inflammatory, diseases, Rheumatoid, arthritis, atopic, dermatitis, eczema, type I diabetes, hemolytic, anemia, dermatoses, bowel, gastrointestinal, Crohn's disease, ulcerative, colitis, multiple, sclerosis, myasthenia, gravis, pruritus, inflammation, psoriasis, cirrhosis, Systemic, lupus, erythematosus.
 
Posted DateOct 14, 2013 2:36 PM

Office of Technology Transfer
269 Grigg Hall
Charlotte, NC 28223-001
(704) 687-8012
 

Copyright ©2008 Office of Technology Transfer-UNC Charlotte. All Rights Reserved